| dc.creator | Siokas V., Aloizou A.-M., Tsouris Z., Liampas I., Liakos P., Calina D., Docea A.O., Tsatsakis A., Bogdanos D.P., Hadjigeorgiou G.M., Dardiotis E. | en |
| dc.date.accessioned | 2023-01-31T09:56:44Z | |
| dc.date.available | 2023-01-31T09:56:44Z | |
| dc.date.issued | 2021 | |
| dc.identifier | 10.3390/jcm10030381 | |
| dc.identifier.issn | 20770383 | |
| dc.identifier.uri | http://hdl.handle.net/11615/79025 | |
| dc.description.abstract | Background: Parkinson’s disease (PD) is the second commonest neurodegenerative disease. The genetic basis of PD is indisputable. Both ADORA2A rs5760423 and CYP1A2 rs762551 have been linked to PD, to some extent, but the exact role of those polymorphisms in PD remains controversial. Objective: We assessed the role of ADORA2A rs5760423 and CYP1A2 rs762551 on PD risk. Methods: We genotyped 358 patients with PD and 358 healthy controls for ADORA2A rs5760423 and CYP1A2 rs762551. We also merged and meta-analyzed our data with data from previous studies, regarding these two polymorphisms and PD. Results: No significant association with PD was revealed (p > 0.05), for either ADORA2A rs5760423 or CYP1A2 rs762551, in any of the examined genetic model of inheritance. In addition, results from meta-analyses yield negative results. Conclusions: Based on our analyses, it appears rather unlikely that ADORA2A rs5760423 or CYP1A2 rs762551 is among the major risk factors for PD, at least in Greek patients with PD. © 2021 by the authors. Licensee MDPI, Basel, Switzerland. | en |
| dc.language.iso | en | en |
| dc.source | Journal of Clinical Medicine | en |
| dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85101361438&doi=10.3390%2fjcm10030381&partnerID=40&md5=d3f75a95b1c7829f56ef4c84c20cc91d | |
| dc.subject | adenosine A2a receptor | en |
| dc.subject | cytochrome P450 1A2 | en |
| dc.subject | aged | en |
| dc.subject | Article | en |
| dc.subject | case control study | en |
| dc.subject | controlled study | en |
| dc.subject | female | en |
| dc.subject | gene frequency | en |
| dc.subject | genetic association | en |
| dc.subject | genetic model | en |
| dc.subject | genetic risk | en |
| dc.subject | genotype | en |
| dc.subject | human | en |
| dc.subject | inheritance | en |
| dc.subject | major clinical study | en |
| dc.subject | male | en |
| dc.subject | medical ethics | en |
| dc.subject | meta analysis | en |
| dc.subject | molecular genetics | en |
| dc.subject | Parkinson disease | en |
| dc.subject | risk factor | en |
| dc.subject | sex ratio | en |
| dc.subject | single nucleotide polymorphism | en |
| dc.subject | university hospital | en |
| dc.subject | MDPI | en |
| dc.title | ADORA2A rS5760423 and CYP1A2 rs762551 polymorphisms as risk factors for parkinson’s disease | en |
| dc.type | journalArticle | en |
